Cancer survival rates are typically discussed as 5-year relative survival, or as the proportion of patients alive five years after diagnosis. In the United States, national data shows that in women with ovarian cancer, 46% are still alive five years after diagnosis.
Ovarian cancer survival remains poor due to a number of factors, some of which include: the absence of a reliable screening test, the high number of women diagnosed with late-stage disease, and the tendency for ovarian cancer to eventually resist chemotherapy and recur. Roswell Park researchers are currently working to find solutions to each of these factors.
Patients diagnosed with early-stage disease fare significantly better. Nationally, women with early stage, localized disease, where the cancer is confined to the primary site, 92.5% are still alive five years after diagnosis. Among women whose cancer has spread to regional lymph nodes, the survival rate drops to 74.5%. Women with ovarian cancer that has metastasized to other body areas, called distant disease, have a survival rate of 29.2%. Learn more ovarian cancer statistics from the National Cancer Institute.
Ovarian Cancer Survival at Roswell Park
At Roswell Park, we continually monitor, measure and evaluate all our patient outcomes and survival, and we compare our data to national data collected by the Surveillance, Epidemiology, and End Results (SEER) Program. Roswell Park’s Survival Data are shown below.
AJCC Stage Group Ovarian Cancer
Stage at diagnosis for CY 2014-2015
This pie chart illustrates how many patients with ovarian cancer have advanced disease at the time of diagnosis.1, 2
Five-Year Relative Survival, Ovarian Cancer, Stages I-IV
Cases Diagnosed 2006-2013
The following graph illustrates the survival rates of patients with ovarian cancer at Roswell Park, compared to the survival rates nationwide.3
Relative Survival compares the actual observed survival with the expected survival of persons unaffected by cancer.
|Roswell Park 5-Year Relative Survival for Ovarian Cancer|
|N=117||Roswell Park Stage I||98%||98%||95%||94%||94%|
|N=45||Roswell Park Stage II||97%||88%||88%||88%||88%|
|N=179||Roswell Park Stage III||85%||70%||57%||47%||41%|
|N=102||Roswell Park Stage IV||71%||63%||55%||49%||38%|
After Treatment Surveillance
We follow national guidelines for evidence-based surveillance to monitor for earliest signs and symptoms of recurrence that includes:
- Physical exams
- Screening with tumor markers
- Monitoring for late side effects of treatment
- Updated information about new strategies and potential clinical trials
Survivorship & Supportive Care Center
This center brings together many of Roswell Park’s clinical and supportive services, specifically designed for patients who have completed active treatment. Our cancer survivorship experts can help:
- Detect and manage any complications or side effects from your disease or its treatment.
- Restore body and soul with rehabilitative therapy, nutrition counseling, and emotional support and guidance.
- Create a plan that will be your roadmap to your healthiest lifestyle possible.
1American Joint Commission on Cancer (AJCC) Stage I-IV Ovarian Cancer
2The International Federation of Obstetricians and gynecologists (FIgO) staging rules are incorporated into the AJCC staging system
3Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying) - Linked To County Attributes - Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. Accessed February 8, 2017.